Some researchers have modified human ASCs to boost TRAIL production under TGF-β signaling via a SMAD4-controlled minimal promoter, taking advantage of the increased TGF-β expression in glioblastoma compared to normal brain tissue [45]. Here, TGFB1 is linked to glioblastoma.